Turning Point Therapeutics

$106.05
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.47 (+1.41%) Today
$0.00 (0.00%) As of 11:00 PM UTC after-hours

Why Robinhood?

You can buy or sell TPTX and other stocks, options, and ETFs commission-free!

About TPTX

Turning Point Therapeutics, Inc. engages in the discovery and development of precision medicines for cancer and other diseases. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by J. Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. The listed name for TPTX is Turning Point Therapeutics, Inc. Common Stock.

CEO
Athena Countouriotis
Employees
95
Headquarters
San Diego, California
Founded
2013
Market Cap
5.11B
Price-Earnings Ratio
Dividend Yield
Average Volume
326.84K
High Today
$107.10
Low Today
$103.48
Open Price
$105.29
Volume
145.12K
52 Week High
$122.85
52 Week Low
$31.30

Collections

TPTX Earnings

-$0.89
-$0.73
-$0.58
-$0.42
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Estimated
-$0.54 per share
Actual
-$0.42 per share

You May Also Like